Boston Tech
Vertex Bought Crinetics for $10 Billion, Because Boston Enjoys Expensive Homework
Vertex agreed to buy Crinetics for $10 billion on July 6, giving Boston biotech a huge endocrinology bet and a fresh test beyond cystic fibrosis.
Boston Tech
Vertex agreed to buy Crinetics for $10 billion on July 6, giving Boston biotech a huge endocrinology bet and a fresh test beyond cystic fibrosis.
Boston Tech
Vertex's July 1 FDA expansion makes Casgevy available to children ages 2 and up, a major Boston biotech milestone with real access hurdles.